Oncimmune Holdings PLC Result of AGM (0666J)
30 November 2018 - 9:46PM
UK Regulatory
TIDMONC
RNS Number : 0666J
Oncimmune Holdings PLC
30 November 2018
30 November 2018
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Result of Annual General Meeting
Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer
detection company developing and commercialising its proprietary
EarlyCDT(R) platform technology, announces that at the Annual
General Meeting held earlier today, all resolutions were duly
passed.
The results of the proxy vote on each of the resolutions will be
available on the Company's website shortly.
-Ends-
For further information:
Oncimmune Holdings plc
Adam Hill, Chief Executive Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Andrew Jones, John Goold
+44 (0)20 3829 5000
Bryan, Garnier & Co Limited (Joint Broker)
Phil Walker, Dominic Wilson
+44 (0)20 7332 2500
Berenberg (Joint Broker)
Toby Flaux, Alix Mecklenburg-Solodkoff
+44 (0)20 3207 7800
Media enquiries:
Consilium Strategic Communications
Chris Gardner, Matthew Neal, Lindsey Neville
Oncimmune@consilium-comms.com
+44 (0)20 3709 5708
About Oncimmune
Beating cancer, one test at a time
Oncimmune is a leader in the development, manufacture and
commercialisation of personalised immunodiagnostics for the
screening, detection and care of cancer. Oncimmune is changing how
clinicians, researchers and patients view, diagnose and treat
cancer. Our technology detects evidence of the body's natural
response to cancer, enabling detection 4 years or more before
standard clinical diagnosis. Our tests facilitate clinical
decision-making and are complementary to diagnostic technologies,
making them valuable additions to established and new care
pathways. We partner with leading developers and distributors to
make our technology available globally.
Oncimmune was founded in 2002 and launched its platform
technology in 2009, followed by its first commercial tests,
EarlyCDT(R) -Lung and EarlyCDT(R) -Liver. To date, over 155,000
tests have been performed for patients worldwide and EarlyCDT(R)
-Lung is being used in the largest-ever randomised trial for the
early detection of lung cancer using biomarkers, the National
Health Service (NHS) ECLS study of 12,210 high-risk smokers in
Scotland. Oncimmune, headquartered in Nottingham, UK with a CLIA
lab in Kansas, US and offices in London, UK and Shanghai, China.
Oncimmune joined the Alternative Investment Market (AIM) of the
London Stock Exchange in May 2016 under the ticker ONC.L.
For more information, visit http://oncimmune.com/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RAGFDLFSSFASELF
(END) Dow Jones Newswires
November 30, 2018 05:46 ET (10:46 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024